Kathleen Harnden, MD
Medical Oncology · Fairfax, VANPI 1033438270
Payments from drug & device makers
Across 509 payments — averaging $7913.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.9M
- Genentech, Inc.$442K
- AstraZeneca$390K
- Radius Health, Inc.$275K
- Stemline Therapeutics Inc.$247K
- Napo Pharmaceuticals Inc$231K
- plus $533K from 15 others
Across 13 payments — averaging $1216.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$14K
- Radius Health, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 15 | $1,908,775 |
| Genentech, Inc. | 30 | $441,875 |
| AstraZeneca | 17 | $390,426 |
| Radius Health, Inc. | 10 | $275,335 |
| Stemline Therapeutics Inc. | 99 | $246,977 |
| Napo Pharmaceuticals Inc | 24 | $231,261 |
| G1 Therapeutics, Inc. | 22 | $155,892 |
| Daiichi Sankyo Inc. | 67 | $87,409 |
| Pharmacosmos Therapeutics Inc. | 24 | $82,936 |
| Pfizer | 119 | $66,522 |
| Macrogenics, Inc. | 6 | $34,294 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32,317 |
| Merck | 22 | $29,890 |
| Seagen Inc. | 29 | $27,572 |
| Eisai Inc. | 13 | $15,188 |
| Astrazeneca UK Limited | 1 | $971 |
| Genentech USA, Inc. | 3 | $160 |
| Bone Support Inc. | 1 | $127 |
| Tempus AI, Inc | 1 | $87 |
| Incyte Corporation | 1 | $76 |
| Gilead | 3 | $54 |
How this compares
$4,028,142 in reported general payments places this provider in the 95th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Fairfax
- Alexander SpiraFairfax$69.5M
- Adam CohenFairfax$2.2M
- Janakiraman SubramanianFairfax$1.9M
- Timothy CannonFairfax$1.9M
- Anne FavretFairfax$1.9M
- John DeekenFairfax$1.6M
- Arthur WinerFairfax$923K
- Nagla Abdel KarimFairfax$911K
- Amin BenyounesFairfax$824K
- Eun-Mi YuFairfax$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.